As a specialist IP firm, Brigard Castro frequently advises life sciences clients on IP issues, including complex patent matters. On the regulatory side, the team is noted for its experience in representing healthcare entities on regulatory compliance and related administrative law disputes. The team is also well versed in advising corporations in the pharmaceutical, healthcare and food and beverage industries — among others — on transactional work, where it can link up with associated full-service firm, Brigard Urrutia. Managing partner Juan Pablo Cadena fronts a group that also draws on trade mark specialist Martín Torres and senior associate Laura Ángel Jaramillo.
Legal 500 Editorial commentary
Key clients
- Janssen Biotech
- Celgene Corporation
- Sinovac Group (Sinovac Biotech Co / Sinovac (Dalian) Vaccine Technology Co / Sinovac Life Sciences Co)
- Recordati Rare Diseases
- Levapan
- Opella Healthcare Colombia
- Multicare
- Sysnab
Work highlights
- Advised Sinovac Group, together with Brigard Urrutia, on the risks associated with participation in a state contract concerning an ambitious technology transfer project.
- Advised Celgene Corporation on a nullity proceeding involving a patent related to the chemical composition used as a medicine for cancer treatment and inflammatory chronical diseases.
- Advised Janssen Biotech in a nullity proceeding seeking to revoke the Patent Office’s decision to refuse a patent.
Practice head
The lawyer(s) leading their teams.
Juan Pablo Cadena